Evaluation of probiotics effects on bilirubin level

Evaluation of probiotics effects on bilirubin level in patient with neonatal jaundice admitted in the hospital

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017061018974N3

Enrollment

Registered

2017-07-25

Start date

2016-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal hyperbilirubinemia. P59.9 Neonatal jaundice, unspecified Physiological jaundice (intense)(prolonged) NOS

Interventions

Intervention 1: Infants in the study group(treated)receive,about 5 drops probiotics 3 times a day + phototherapy probiotic is included Lactobacillus rhamnosus - Lactobacillus reuteri - Bifidobacteriu

Treatment - Drugs

Infants in the study group(treated)receive,about 5 drops probiotics 3 times a day + phototherapy probiotic is included Lactobacillus rhamnosus - Lactobacillus reuteri - Bifidobacterium infanti.

control group: Distilled water 5 drops/3 times day+phototherapy Distilled waters are produced by shahid ghazi in 2 cc package conventional phototherapy :6 lamp photo mark PHilips TL 20/120 made

Eligibility

Sex/Gender

All

Age

1 Days to 10 Days

Inclusion criteria

Inclusion criteria: Inclusion criteria: term infants with age between 3-10 days and gestational age of 42-37 weeks , birth weight equals or more than 2500 g , and bilirubin 12.9-up mg / dL at the start of phototherapy, and fed only by breast milk.Exclusion criteria: infants with blood disorders family, having signs of hemolysis due to blood group incompatibility, internal bleeding indoors due to complications of traumatic birth (exp : cephalohematom), suspected neonatal infection such as chorioamnionitis, intrauterine infection, sepsis and urinary tract infection, perinatal hypoxic newborns, having thyroid dysfunction, distress or respiratory failure, malfunction regulate body temperature and metabolic, hemodynamic instability and congenital heart disease, a history of maternal use of phenobarbital during the last month of pregnancy venous hematocrit 65%

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bilirubin level. Timepoint: from 1 to 4 days. Method of measurement: serum lilirubin level.	—

Secondary

Measure	Time frame
Defecations times. Timepoint: 1 and 4 days. Method of measurement: mother report.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsimin gheini

kermanshah university of medical sceinces

simingheini@yahoo.coms.gheini@kums.ac.ir+98 83 3721 8204

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026